
    
      -  The screening period = up to 4 weeks prior to the first administration of combined
           therapy

        -  The treatment period = 3 months of combined therapy. A safety follow-up of 42 to 49 days
           after the last dose of treatment is planned for all patients.

        -  The follow-up period: Patients who are not progressing at the end of study treatment
           will be followed until progression or initiation of another anti-lymphoma therapy. All
           patients will be followed for two years to evaluate survival.
    
  